Showing 161-170 of 279 results for "".
You Don’t Have Male
https://practicaldermatology.com/topics/practice-management/you-dont-have-male/23084/Male cosmetic patients are hard to come by. Here’s why!Get Ready: The Biosimilars Are Here
https://practicaldermatology.com/topics/psoriasis/get-ready-the-biosimilars-are-here/20662/Recent developments mean that biosimilars are finally hitting the US market.New Drugs for Treating Fungal Infections
https://practicaldermatology.com/topics/general-topics/new-drugs-for-treating-fungal-infections/21426/A review of recent developments for efficacious treatment.Retaliation Rules ... Without Rules
https://practicaldermatology.com/topics/editorial/retaliation-rules-without-rules/26653/Practical Dermatology Chief Medical Editor and dermatologist Neal Bhatia, MD, FAAD, reflects on the dynamics of medical board complaints, their impact on careers, and what pracitioners need to keep in mind when dealing with challenges.A Case of Melanoma on the External Ear of a Young Man
https://practicaldermatology.com/topics/skin-cancer-photoprotection/a-case-of-melanoma-on-the-external-ear-of-a-young-man/20461/Recent Developments
https://practicaldermatology.com/columns/recent-developments/recent-developments/20889/Recent Developments
https://practicaldermatology.com/columns/recent-developments/recent-developments/20905/Recent Developments
https://practicaldermatology.com/columns/recent-developments/recent-developments/21078/Chief Academy; Optimize Patient Testimonials; AADA Legislative Conference Grant Opportunities; AMA Medical Education Updates
https://practicaldermatology.com/youngmd-connect/resident-resource-center/chief-academy-optimize-patient-testimonials-aada-legislative-conference-grant-opportunities-ama-medical-education-updates/21160/2024 In Review: This Year's Trends in Dermatology
https://practicaldermatology.com/topics/feature/2024-review-years-trends-dermatology/29886/As the year comes to a close, Practical Dermatology asked Editorial Board members about trends from 2024—what was hot, what was not, new approvals that lived up to the hype, important new research, and other observations from the past year.